Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2006-02-14
2006-02-14
Johannsen, Diana B. (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S007100, C435S091200, C435S091510, C536S023500, C536S024310, C530S350000
Reexamination Certificate
active
06998232
ABSTRACT:
There is provided a method of diagnosing the presence of bladder cancer in a patient by analyzing a tissue sample from the patient for the presence of a least one expressed gene wherein the presence of the expressed gene is indicative of bladder cancer. Also provided by the present invention is a polynucleotide sequence whose expression is indicative of bladder cancer. A marker for bladder cancer is also provided. There are also provided methods of diagnosing bladder cancer by screening for the presence of at least one expressed gene wherein the presence of the expressed gene is indicative of bladder cancer. Methods of treating and regulating bladder cancer-associated pathologies by administering to a patient a therapeutically effective amount of chemical compound are also provided.
REFERENCES:
patent: 3791932 (1974-02-01), Schuurs et al.
patent: 3839153 (1974-10-01), Schuurs et al.
patent: 3850578 (1974-11-01), McConnell
patent: 3850752 (1974-11-01), Schuurs et al.
patent: 3853987 (1974-12-01), Dreyer
patent: 3867517 (1975-02-01), Ling
patent: 3879262 (1975-04-01), Schuurs et al.
patent: 3901654 (1975-08-01), Gross
patent: 3935074 (1976-01-01), Rubenstein et al.
patent: 3984533 (1976-10-01), Uzgiris
patent: 3996345 (1976-12-01), Ullman et al.
patent: 4034074 (1977-07-01), Miles
patent: 4098876 (1978-07-01), Piasio et al.
patent: 4439194 (1984-03-01), Harwood et al.
patent: 4447224 (1984-05-01), DeCant et al.
patent: 4447233 (1984-05-01), Mayfield
patent: 4475196 (1984-10-01), La Zor
patent: 4486194 (1984-12-01), Ferrara
patent: 4487603 (1984-12-01), Harris
patent: 4666828 (1987-05-01), Gusella
patent: 4683202 (1987-07-01), Mullis
patent: 4736866 (1988-04-01), Leder et al.
patent: 4801531 (1989-01-01), Frossard
patent: 4866042 (1989-09-01), Neuwelt
patent: 4879219 (1989-11-01), Wands et al.
patent: 4925678 (1990-05-01), Ranney
patent: 4959217 (1990-09-01), Sanders et al.
patent: 5011771 (1991-04-01), Bellet et al.
patent: 5167616 (1992-12-01), Haak
patent: 5169383 (1992-12-01), Gyory
patent: 5175383 (1992-12-01), Leder et al.
patent: 5175384 (1992-12-01), Krimpenfort et al.
patent: 5175385 (1992-12-01), Wagner et al.
patent: 5192659 (1993-03-01), Simons
patent: 5221778 (1993-06-01), Byrnes et al.
patent: 5225182 (1993-07-01), Sharma
patent: 5225347 (1993-07-01), Goldberg et al.
patent: 5272057 (1993-12-01), Smulson et al.
patent: 5281521 (1994-01-01), Trojanowski et al.
patent: 5288846 (1994-02-01), Quertermous et al.
patent: 5298422 (1994-03-01), Schwartz et al.
patent: 5347075 (1994-09-01), Sorge
patent: 5360735 (1994-11-01), Weinshank et al.
patent: 5387742 (1995-02-01), Cordell
patent: 5422243 (1995-06-01), Jalkanen et al.
patent: 5464764 (1995-11-01), Capecchi et al.
patent: 5487992 (1996-01-01), Capecchi et al.
patent: 5856136 (1999-01-01), Au-Young
patent: 6207380 (2001-03-01), Billing-Medel et al.
patent: 6335170 (2002-01-01), Orntoft
patent: WO0122864 (2001-04-01), None
Rintala, M. et al. Association of syndecan-1 with tumor grade and histology in primary invasive cervical carcinoma. Gynecologic Oncology 75(3):372-378 (Dec. 1999).
U.S. Appl. No. 09/670,672, filed Sep. 27, 2000, Feinstein and Mor.
Ozen, “Bladder Cancer,”Curr. Opin. Oncol.10(3):273-278 (1998).
Torti and Lum, “The Biology and Treatment of Superficial Bladder Cancer,”J. Clin. Oncol.2(5):505-531 (1984).
Grossman, “New Methods for Detection of Bladder Cancer,”Semin. Urol. Oncol.16(1):17-22 (1998).
Sarver et al. “Exploring Catalytic RNAs (Roiboxymes) as Anti-HIV Agents,” pp. 305-325 inGene Regulation and AIDSby Papas, Portfolio Publishing Co. Woodlands, Texas (1990).
Culver, “Site-Directed recombinant for repair of mutations in the human ADA gene,” (Abstract)Antisense DNA&RNA based therapeutics, Coronado, California (1998).
Lacombe et al., “Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guerin therapy; correlation to clinical outcome,”J. Urol.153(3) Part 1:564-572 (1995).
Herskowitz “Functional inactivation of genes by dominant negative mutations”Nature329: 219-222 (1987).
Hudson and Herr, “Carcinoma in situ of the bladder,”J. Urol.153(3) Part 1:564-572 (1995).
Rosenthal et al., “Human bladder tumour cDNA library derived EST 15”, Geneseq032802 Accession No. AAZ24403, submitted Feb. 2000.
National Institutes of Health, Mammalian Gene Collection, “Homo sapiens cDNA clone”, EST Accession No. BG291376, submitted Feb. 2000.
Quark Biotech Inc., “Bladder cancer-associated sequence, TCC75E3”, Geneseq032802 Accession No. AAS01308, submitted Jul. 2001.
Quark Biotech Inc., “Bladder cancer-associated sequence, TCC94G3”, Geneseq032802 Accession No. AAS01297, submitted Jul. 2001.
Billing-Medel et al., “Sequence 7 from patent US 6,207,380”, GeneEmbl Accession No. AR139477, submitted Jun. 2001.
Burke and Olson, “Preparation of Clone Libraries in yeast Artifical Chromosome Vectors” inMethods in Enzymology, vol. 194, “Guide to Yeast Genetics and Molecular Biology”, Guthrie and Fink (eds.), Academic Press, Inc. Chap. 17, pp. 251-270 (1991).
Capecchi, “Altering the genome by homologous recombination,”Science244:1288-1292 (1989).
Cregg et al., “Recent Advanced in the Expression of Foreign Genes inPichia pastoris,” Bio/Technology 11:905-910 (1993).
Davies et al., “Targeted alterations in yeast artifical chromosomes for inter-species gene transfer,”Nucleic Acids Research20(11):2693-2698 (1992).
Diatchenko et al., “Suppression subtractive hybridization: A method for generating differentially regulared or tissue-specific cDNA probes and libraries,”Proc. Natl. Acad. Sci.93:6025-6030 (1996).
Dickinson et al., “High frequency gene targeting using insertional vectors,”Human Molecular Genetics2(8):1299-1302 (1993).
Duff and Lincoln, “Insertion of pathogenic mutation into a yeast artificial chromosome containing the human APP gene and expression in ES cells,” inResearch Advances in Alzheimer's Disease and Related Disorders(1995).
Gilboa et al., “Transfer and expression of cloned genes using retroviral vectors,”BioTechniques4(6):504-512 (1986).
Huston et al., “Protein engineering of single chain Fv analogs and fusion proteins,” inMethods in Enzymology, JJ Langone, ed.; Academic Press, New York, 203:46-88 (1991).
Huxley et al. “The human HPRT gene on a yeast artificial chromosome is function when transferred to mouse cells by cell fusion,”Genomics9:742-750 (1991).
Jakobovits et al. “Germ-line transmission and expression of a human-derived yeast artificial chromosome,”Nature362:255-261 (1993).
Johnson and Bird, “Construction of single-chain Fvb derivatives of monovclonal antibodies and their production inEscherichia coli,” inMethods in Enzymology, JJ Langone, ed.; Academic Press, New York, 203:88-99 (1991).
Lamb et al., “Introduction and expression of the 400 kilobase precursor amyloid gene in transgenic mice,”Nature Genetics5:22-29 (1993).
Mernaugh and Mernaugh “An overview of phage-displayed recombinant antibodies,” inMolecular Methods in Plant Pathology, Singh and Singh, eds.; CRC Press, Inc., Boca Roton, Florida, pp 359-365 (1995).
Pearson and Choi, “Expression of the human β-amyloid precursor protein gene from a yeast artificial chromosome in transgenic mice,”Proc. Natl. Acad. Sci. USA90:10578-10582 (1990).
Rothstein, “Targeting, disruption, replacement, and allele rescue: integrative DNA transformation in yeast” inMethods in Enzymology, vol. 194, “Guide to Yeast Genetics and Molecular Biology,” Guthrie and Fink (eds.), Academic Press, Inc. Chap. 19, pp. 281-301 (1991).
Schedl et al., “A yeast artificial chromosome covering the tyrosinase gene confers copy number-dependent expression in transgenic mice,&#x
Feinstein Elena
Mor Orna
Cooper & Dunham LLP
Johannsen Diana B.
Quark Biotech, Inc.
White John P.
LandOfFree
Methods of diagnosing bladder cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of diagnosing bladder cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of diagnosing bladder cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3681395